NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Journey Medical Corporation (DERM) Stock Analysis

Journey Medical Corporation (DERM) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

DERM

$7.86

−$0.04 (−0.51%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DERM with… →

DERM Key Statistics

As of Sep 4, 2026
Trading
Open
$8.02
Previous Close
$7.90
Day's Range
7.80–8.15
52-Week Range
4.31–9.56
Volume
51.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
$221.84M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.22
Financials (FY)
Revenue (FY)
$61.86M+10.20%
Net Income (FY)
−$11.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
−8.95%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
22.22M
1-Year Return
+11.33%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
244.10K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DERM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.95%
2025+97.19%
2024−32.12%
2023+200.00%
2022−64.31%
2021 (partial year)−45.66%

As of September 4, 2026.

DERM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$61.86M−$11.43M−18.5%
2024$56.13M−$14.67M−26.1%
2023$79.18M−$3.85M−4.9%
2022$73.67M−$29.63M−40.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$61.86M$40.93M−$8.17M−$11.43M−18.5%
2024$56.13M$35.26M−$18.23M−$14.67M−26.1%
2023$79.18M$56.29M$1.07M−$3.85M−4.9%
2022$73.67M$42.89M−$27.52M−$29.63M−40.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DERM Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricDERMDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio3.252.3042% above
Profit margin−8.95%−3.14%5.8 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Journey Medical Corporation (DERM) at $221.84M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 58.

The most recent close on file for DERM is $7.86, dated September 4, 2026. That is −$0.04 (−0.51%) against the previous close. Over the past 52 weeks the price has ranged from $4.31 to $9.56. The latest close sits 82.37% above that 52-week low.

Financial Health

In fiscal 2025, Journey Medical Corporation reported revenue of $61.86M. That is +10.20% against the prior fiscal year, when revenue was $56.13M. The same year closed with a net loss of $11.43M. The reported profit margin is −8.95%. That is 5.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.22.

Across the 4 fiscal years on file, revenue moves from $73.67M in 2022 to $61.86M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 3.25. On price-to-sales that is 41.7% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.1. Daily returns over the trailing 4 years annualize to a volatility of 90.75%. The trailing one-year price return is +11.33%. Measured over 3 years, that is +55.02% a year compounded.

Growth & Income

The record shows no dividend for DERM.

Across the complete calendar years on file, 2023 returned +200.00% and 2022 returned −64.31%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +1.95% year to date.

Peer Comparison

Journey Medical Corporation (DERM) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Journey Medical Corporation DERM $221.84M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Journey Medical Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Journey Medical Corporation

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Visit website →